相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
Kaitlyn J. Andreano et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come
Craig Furman et al.
CANCER RESEARCH (2019)
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ER covalent antagonist (SERCA)
Nathalie Rioux et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
George S. Tria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer
Xiaoling Puyang et al.
CANCER DISCOVERY (2018)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Sean W Fanning et al.
eLife (2016)
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
Fiona Garner et al.
ANTI-CANCER DRUGS (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu et al.
JAMA ONCOLOGY (2015)
Estrogen Receptor Mutations in Breast Cancer-New Focus on an Old Target
Corrinne V. Segal et al.
CLINICAL CANCER RESEARCH (2014)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Philipp Y. Maximov et al.
CURRENT CLINICAL PHARMACOLOGY (2013)
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: Addressing the Core Issue in the Design of Estrogen Receptor Ligands
John A. Katzenellenbogen
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
Kathleen I. Pritchard et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Kendall W. Nettles et al.
NATURE CHEMICAL BIOLOGY (2008)
Prognostic effect of estrogen receptor status across age in primary breast cancer
Niels Bentzon et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Structure activity relationship for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene
Cassia R. Overk et al.
CHEMMEDCHEM (2007)
Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation
H Liu et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2005)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
分享论文
